Breaking Finance News

STRATEC Biomedical (ETR:SBS) stock price target upped to 53.00EUR, released a research note earlier today by Joh. Berenberg Gossler & Co. KG

Reporting as potential upside of 0.01%, Joh. Berenberg Gossler & Co. KG upped the price target of STRATEC Biomedical (ETR:SBS) to 53.00EUR

On 9/2/2016, Warburg Research released a statement about STRATEC Biomedical (ETR:SBS) upped the target price from 0.00EUR to 65.00EUR that suggested an upside of 0.18%.

Having a price of 52.61EUR, STRATEC Biomedical (ETR:SBS) traded 0.74% higher on the day. With the last stock price up 19.18% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. SBS has recorded a 50-day average of 9.13EUR and a two hundred day average of 8.01EUR. Trade Volume was down over the average, with 914,891 shares of SBS changing hands under the typical 2,135,280

Recent Performance Chart

STRATEC Biomedical (ETR:SBS)

STRATEC Biomedical has PE ratio of 16.55 with a one year low of 3.46EUR and a one year high of 9.83EUR and has a market capitalization of 0 EUR.

A total of 3 brokerages have issued a ratings update on SBS. zero firms rating the stock a strong buy, 0 equity analysts rating the company a buy, 0 brokers rating the stock a hold, zero brokerages rating the stock a underperform, and finally 0 analysts rating the company a sell with a one year target of 28.48EUR.

About STRATEC Biomedical (ETR:SBS)

STRATEC Biomedical AG (STRATEC) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics. STRATEC's partners market Company's products to pharmaceutical laboratories, blood banks and research institutes throughout the world. STRATEC Group operats through its four consolidated subsidiaries in Switzerland, the United Kingdom, Germany as well as the United States, comprising STRATEC Biomedical Switzerland AG, STRATEC Biomedical UK, Ltd, STRATEC Molecular GmbH and STRATEC Biomedical USA, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *